Aspen is the largest pharmaceutical company in Africa and and has a proud heritage dating back more than 160 years. It is committed to sustaining life and promoting healthcare through increasing access to its high quality, effective, affordable medicines and products.
The South African business provides a diverse basket of branded, generic, OTC, consumer health and infant nutritional products which are supplied to pharmacies, retail pharmacy chains, hospitals, clinics, prescribing specialists, dispensing general practitioners, managed healthcare funders and retail stores across the private and public sectors in South Africa.
Aspen’s product ranges cover a number of therapeutic categories. These include anaesthetics, analgesics, ARVs, blood and haemopoetic, cardio vascular system, central nervous system ear, nose and throat, endocrine system, gastro-intestinal tract, infant nutritional products, musculo-skeletal agents, NS aids, oncology, oral hygiene, respiratory system and urinary tract system and more.
Aspen has 26 pharmaceutical manufacturing facilities on 18 pharmaceutical manufacturing sites on 6 continents. Click here to view Aspen’s global manufacturing capabilities.
Aspen’s manufacturing centre is based in South Africa and facilities in Port Elizabeth and East London produce a high volume of tablets, capsules, liquids, semi-solids, eye drops, liquid vials, hormonal ampoules and vials, lyophilised vials, infant milk forumula and liquid UHT.
As at 30 June 2014, IMS valued the South African private pharmaceutical sector at R29,9 billion and Aspen was ranked as the number one pharmaceutical company in the private sector, with a 15,8% share. In the private sector, four out of the top 20 largest products was an Aspen product and four out of the top five generic products supplied in the private sector are for Aspen products. Almost one in every four scripts dispensed by South African pharmacists is for an Aspen product, as recorded by ImpactRx.
Aspen has a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to its high quality affordable medicines and products.
Aspen has a market capitalisation of approximately US$10 billion, is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks among the top 20 listed companies on this exchange.
As a leading global player in specialty, branded and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential.
Aspen has a strong global presence in both emerging and developed countries with more than 60 established business operations in approximately 50 countries. The Group has 26 manufacturing facilities at 18 sites across 6 continents and has more than 10 000 employees.
Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the US FDA, TGA and EMA. Aspen’s manufacturing capabilities are scaleable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals.